Neuromuscular

Italfarmaco is expected to report topline data from the phase 3 EPYDIS trial in June 2022.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 10, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

Nearly two-thirds of patients achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months.

Results from a 24-week phase 2a trial and its 2-year extension suggest that patients taking vamorolone experienced motor outcome improvements compared to corticosteroid-naïve individuals.

Here's what is coming soon to NeurologyLive.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The results confirmed that roughly almost 15% of cases are linked to genes and ultimately led to recommendations for more tailored treatments of 3 patients.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

The free webcast programs, which will focus on cannabis use in MS and MS nursing care, will earn participants up to 3 CE credits each.

The findings were consistent with the drug's previously reported safety profile and no new safety signals were observed.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

The neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.

The chief medical officer at Cure SMA spoke to the ongoing work that the organization does in advocating for patients with spinal muscular atrophy, particularly for newborn screening.